Breast Cancer, Lymphedema
Conditions
Brief summary
To compare the effectiveness of usual treatments for lymphedema \[massage and elastic compression sleeve, instituted at-risk and before the development of swelling (lymphedema)\], compared to the use of a newly-marketed device, the Flexitouch, which electronically simulates the effect of massage upon lymph flow.
Detailed description
The current investigation is designed to prospectively evaluate the potential for simple, effective lymphedema prophylaxis in breast cancer survivors who show early evidence of high-risk status. There is growing evidence that the mechanisms of lymphatic repair after injury are mediated through lymphatic flow. Accordingly, this study assess if physical measures designed to prophylactically augment lymphatic flow after surgical interventions for breast cancer (eg, Flexitouch and manual lymphatic massage) will reduce the incidence of lymphatic stagnation, assessed as incidence of lymphedema, when compared to patients who receive conventional watch and wait interventions (observation). The specific aims of the study are 1. to prospectively assess the presence of newly developing lymphedema in each study subgroup through serial assessment of segmental interstitial fluid content by multiple frequency bioimpedance 2. to evaluate the preventive interventions in a prospective, randomized fashion, contrasting the responses of equivalent numbers of patients randomized to 2 experimental arms and the control arm of the study 3. to correlate the bioimpedance findings with concurrently derived, serial assessments of limb volume Recent advances in the medical understanding of the biological processes of lymphatic development and repair suggest that these mechanisms may be able to be manipulated to enhance the regenerative responses in the lymphatic vasculature following injury. Breast cancer-associated lymphedema is a model of such an acquired form of lymphatic vasculature insufficiency. Clinically, this poses a substantial clinical problem. It is estimated at 1woman in 4 who survives a breast cancer intervention will develop lymphedema, often progressively. The appearance of lymphedema has documented adverse effects on physical and psychologically well-being. New insights into lymphatic repair suggest that such mechanisms can be employed in a prophylactic fashion to forestall or eliminate the development of lymphedema. This proposal investigates this hypothesis in a prospective fashion, using a randomized trial design in 80 patients enrolled at the time of breast cancer surgery. If the investigation documents a beneficial effect of preventive measures, it could have a profound impact on subsequent breast cancer care. These measures are simple and cost-effective and, could help to eliminate the impact of a substantial detractor to the improved longevity and health that breast cancer survivors otherwise may expect to enjoy.
Interventions
A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
Sponsors
Study design
Eligibility
Inclusion criteria
* Unilateral breast cancer * Scheduled to undergo breast surgery and axillary lymph node dissection, with or without breast conserving techniques. * Referred to the surgeons of the Stanford University Breast Cancer Program * Capacity to provide informed consent. * All experimental protocols will be reviewed and approved by the Stanford Institutional Review Board for the Protection of Human Subjects.
Exclusion criteria
* Other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate. * Recurrent breast cancer or other forms of pre-existing lymphedema.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy | 36 months | Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups |
| Incidence of Lymphedema (Newly-developing) | 3 years of semi-annual follow-up | Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues. |
Countries
United States
Participant flow
Recruitment details
Enrollment commenced in May 2005 and concluded 13 March 2012. Subjects were recruited from the medical clinics and Stanford University Hospital and Clinics.
Participants by arm
| Arm | Count |
|---|---|
| Group I This group of patients will receive the device. | 27 |
| Group II This group of patients will receive prophylactic MLD | 24 |
| Group III This is the control group; they will receive no treatment | 24 |
| Total | 75 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 8 | 3 | 0 |
Baseline characteristics
| Characteristic | Group II | Group III | Total | Group I |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 5 Participants | 10 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 22 Participants | 19 Participants | 65 Participants | 24 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 0 Participants | 3 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 22 Participants | 24 Participants | 72 Participants | 26 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 9 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) White | 20 Participants | 20 Participants | 57 Participants | 17 Participants |
| Sex: Female, Male Female | 24 Participants | 24 Participants | 75 Participants | 27 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 19 | 5 / 21 | 5 / 22 |
| serious Total, serious adverse events | 0 / 19 | 0 / 21 | 0 / 22 |
Outcome results
Incidence of Lymphedema (Newly-developing)
Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.
Time frame: 3 years of semi-annual follow-up
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flexitouch Device | Incidence of Lymphedema (Newly-developing) | 1 participants |
| Manual Lymphatic Drainage (MLD) | Incidence of Lymphedema (Newly-developing) | 5 participants |
| No Intervention Control | Incidence of Lymphedema (Newly-developing) | 5 participants |
Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy
Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups
Time frame: 36 months
Population: All enrolled patients in the trial who did not withdraw or were lost to follow-up
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Flexitouch Device | Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy | 19 participants |
| Manual Lymphatic Drainage (MLD) | Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy | 21 participants |
| No Intervention Control | Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy | 22 participants |